Llwytho...
SAMHD1 is a barrier to antimetabolite-based cancer therapies
The outcome of acute myelogenous leukemia (AML) therapy depends on the propensity of leukemic blasts to accumulate ara-CTP, the active triphosphate of cytarabine (ara-C). We identified sterile α motif and HD domain-containing protein 1 (SAMHD1) as an ara-CTPase that protects cancer cells from cytara...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Mol Cell Oncol |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Taylor & Francis
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5383367/ https://ncbi.nlm.nih.gov/pubmed/28401188 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2017.1287554 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|